BioProject

The histone methyltransferase EZH2 has been shown to function as a multifaceted molecule which can switch from a transcriptional repressor to an activator inducing a subset of genes that promote oncogenesis, including breast cancer. More...

The histone methyltransferase EZH2 has been shown to function as a multifaceted molecule which can switch from a transcriptional repressor to an activator inducing a subset of genes that promote oncogenesis, including breast cancer. TfR-1, a key mediator in iron absorption, is highly expressed in a variety of tumors and associated with tumor grade, tumor stage and prognosis of patients. However, the known regulation mechanism of TfR-1 mainly remains on post-transcriptional level. To figure out whether TfR-1 expression is under epigenetic control, we examined the influence of EZH2 depletion and inhibition on TfR-1 expression in different subtypes of breast cancer cells. We discovered that EZH2 context-dependently modulates TfR-1 level and manipulates cellular iron uptake. Moreover, we identified TfR-1 as an NF-κB target gene which is positively regulated by EZH2 via constructing a complex with p65-p50 and transcription factor AP-1 in ER- cells. Inversely, TfR-1 is repressed by EZH2 and ER through histone methylation on its promoter in ER+ cells. These findings demonstrated an additional role of EZH2 in promoting breast cancer progression through iron homeostasis regulation and underscore the need for developing context-specific strategy for therapeutic targeting of epigenetic inhibition in breast cancer. Overall design: Examination of H3K27ac modification in MCF-7 cancer cell lines Less...